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ABSTRACT
MicroRNAs (miRNAs) mark a new paradigm of RNA-
directed gene expression regulation in a wide spec-
trum of biological systems. These small non-coding
RNAs can contribute to the repertoire of host-
pathogen interactions during viral infection. This
interplay has important consequences, both for the
virus and the host. There have been reported evi-
dences of host-cellular miRNAs modulating the
expression of various viral genes, thereby playing
a pivotal role in the host–pathogen interaction net-
work. In the hide-and-seek game between the
pathogens and the infected host, viruses have
evolved highly sophisticated gene-silencing
mechanisms to evade host-immune response.
Recent reports indicate that virus too encode
miRNAs that protect them against cellular antiviral
response. Furthermore, they may exploit the cellular
miRNA pathway to their own advantage.
Nevertheless, our increasing knowledge of the
host–virus interaction at the molecular level should
lead us toward possible explanations to viral tro-
pism, latency and oncogenesis along with the devel-
opment of an effective, durable and nontoxic
antiviral therapy. Here, we summarize the recent
updates on miRNA-induced gene-silencing mecha-
nism, modulating host–virus interactions with a
glimpse of the miRNA-based antiviral therapy for
near future.
INTRODUCTION
MicroRNAs (miRNAs) are small  22 nucleotide (nt)
non-coding RNAs (ncRNAs) that play an important
role in the post-transcriptional regulation of gene
expression in a wide range of organisms from unicellular
eukaryotes to multicellular eukaryotes by a variety
of mechanisms. Initially, these were discovered in
Caenorhabditis elegans (1,2), but now they are known to
be widespread in nature (3–8). It therefore comes as no
surprise that viruses, which typically employ many com-
ponents of the host gene expression machinery, also
encode miRNAs (9–16). Thus far, 8619 miRNA genes
have been annotated from 87 organisms of which Homo
sapiens top the list with 695 miRNA genes identiﬁed till
date. These data are available at microRNA Registry
database managed by researchers at University of
Manchester and the Wellcome Trust Sanger Institute
(http://microrna.sanger.ac.uk/sequences) (17). Over the
course of evolution, viruses have developed highly sophis-
ticated mechanisms to exploit the biosynthetic machinery
of host cells and elude the cellular defense mechanisms
(18,19). Present research advances reveal that the complex
interaction between viruses and host cells also involves
miRNA-mediated RNA-silencing pathways (20).
Viruses have a more intricate interaction with the host
cell, which creates problem in inactivating a virus without
doing any harm to the host cell. Combating viral infection
by targeting viral proteins and pathways unique to the
viral life cycle has become possible for a few viruses with-
out unacceptable host cell toxicity (21). Hence, only a few
eﬀective antiviral drugs exist. Viral resistance, sequence
diversity and drug toxicity are signiﬁcant problems for
all antiviral therapies. This has lead toward harnessing
the potential of RNA interference (RNAi) as an innate
antiviral defense mechanism (22,23).
RNAi represents a vital component of the innate anti-
viral immune response in plants and invertebrate animals.
Furthermore, it serves as a host gene-regulation mecha-
nism that is triggered by the expression of highly struc-
tured miRNA molecules. However, role of cellular
miRNAs in the defense against viral infection in mamma-
lian organisms has thus far remained elusive. Hence, it is
important to understand the intricate details regarding the
inﬂuence of viral replication on the abundance and
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proposed that cellular miRNAs may have a substantial
eﬀect on viral evolution and have the potential to regulate
the tissue tropism of viruses in vivo (20). Viruses too
exploit miRNA-induced gene-silencing pathway by encod-
ing their own miRNAs (9,16,24–27). Thus, studying the
changes in miRNA landscape during viral replication may
help us understand the molecular regulation of host
defenses and the attempt by viruses to overcome host
defense during infection. A wide range of complex inter-
actions is possible through miRNA–mRNA coupling
during host–virus interaction (21). In this game of patho-
gen-host interaction, viruses strive to succeed by eﬀective
usage of host machinery and expressing viral proteins,
whereas eﬃcient hosts limit viral invasion by putting up
innate and adaptive antiviral defenses.
The present review discusses the existing intricate details
about the role of miRNAs in virus–host interaction.
Furthermore, it discusses its therapeutic implications
along with the existing resources needed to study such
interaction.
VIRAL miRNAs
Thomas Tuschl and his group at Rockefeller University
reported the existence of viral miRNAs for the ﬁrst time in
Epstein-Barr virus (EBV) (9). Till now, 141 miRNA genes
have been identiﬁed in 15 viruses from three viral families,
herpesvirus, polyomavirus and retrovirus. Herpesvirus
family with three subfamilies, viz., a-, b- and g-herpesvir-
inae express a large number of distinct miRNAs. Among
these, g-herpesvirus encodes maximum number of
miRNAs (9,28,29). EBV of g-herpesvirus subfamily has
the highest number of miRNAs (17). Kaposi’s sarcoma-
associated viruses (KSHV), a member of the g-herpesvirus
subfamily encodes an array of 13 distinct miRNAs, all of
which are expressed at readily detectable levels in latently
KSHV-infected cells. The remaining three members
encoding miRNAs are murine g-herpesvirus 68
(MHV68) (10,30), Rhesus monkey rhadino virus (RRV)
(31) and Rhesus lymphocryptovirus (rLCV) (28).
Furthermore, reports have been published on identiﬁca-
tion of miRNAs encoded by polyomaviruses, viz., BK
polyomavirus (BKV), JC polyomavirus (JCV) and
simian virus 40 (SV40) (11,32), Human cytomegalovirus
(HCMV) (10,25,33); Herpes Simplex virus-1(HSV-1)
(16,26), HSV-2 (34), Murine cytomegalovirus (MCMV)
(13,35) and Marek’s disease virus type 1 and 2 (MDV-1
and MDV-2) (36–38). The details about the viruses, their
pathogenicity in host and miRNAs encoded by them are
provided in Table 1.
miRNA-biogenesis pathway (Figure 1) poses some seri-
ous problem for RNA viruses and a group of DNA
viruses (poxviruses) to encode miRNAs (4). However, it
is possible to overcome these problems by adopting non-
conventional ways. Omoto et al. (46) have reported the
presence of miRNAs in HIV-1 (which is an RNA virus)
infected cells, although extensive studies by Pfeﬀer et al.
(10) as well as Lin and Cullen (47) have failed to conﬁrm
the existence of viral miRNAs in HIV. Recently, Ouellet
et al. (15) have also identiﬁed miRNAs within HIV-1
trans-activation responsive (TAR) element. It is deﬁnitely
essential and still needs further investigation to ﬁnd
whether the expression of TAR miRNAs inﬂuences viral
replication or the eﬃciency of host-antiviral defenses.
BIOGENESIS OF miRNAs
Any understanding of the potential role of miRNAs in
viral pathogenesis and studies into the entire spectrum
of host–virus interactions at the miRNA level requires
an appreciation of the genomic location, transcription
and processing of miRNAs (48,49).
Organization of miRNA genes
Viral miRNA genes are found as single or clustered tran-
scription units (50–52). The genomic location of the virus-
encoded miRNAs is very important and to some extent
linked with their function. miRNAs of a-herpesviruses,
namely HSV-1, MDV-1 and 2 and those of the g-herpes-
viruses, namely KSHV, are located closed to and within
the latency-associated transcript. These miRNAs are asso-
ciated with latent transcription (16,36,38,41). The organi-
zation of viral miRNA genes within their genomes is
provided in Table 1.
Maturation and processing ofmiRNAs
miRNA biogenesis initiates with the transcription of a pri-
miRNA precursor, typically of length ranging from
 200nt to several thousand nts by RNA polymerase II
(Pol II) (53). On the contrary, work of Borchert et al. (54)
showed a miRNA cluster (C19MC) in the human chro-
mosome 19, interspersed among Alu repeats requires
RNA polymerase III (Pol III) for transcription
(54).Viral miRNAs too undergoes similar processing by
Pol II except in a few cases, namely MHV68 miRNAs,
which are transcribed by Pol III (10).
Next step in miRNA processing involves the recogni-
tion and nuclear cleavage of pri-miRNAs by RNase III
enzyme Drosha acting in concert with the double-stranded
RNA-binding protein DGCR8 (DiGeorge-syndrome
critical-region protein 8) in vertebrates (55,56). This gen-
erates  60-nt pre-miRNA hairpin, which is transported
into the cytoplasm by exportin-5 complexed with Ran-
GTP (Figure 1). Here, GTP hydrolysis results in the
release of the pre-miRNA.
Drosha-mediated processing of miRNA genes located
within the open-reading frames and translation of these
protein-coding transcripts must be mutually exclusive. As
in the case of KSHV miRNAs, processing of miR-K10 and
miR-12 within the nucleus must be modulated in such a
way, so that a substantial percentage of KSHV mRNA is
abletoexitthenucleusbeforeDroshacleavage(40).Hence,
it is possible that the regulation of viral mRNA expression
by modulation of Drosha cleavage eﬃciency has a role in
several diﬀerent virus replication cycles.
Drosha independent miRNA processing has been pre-
viously observed in the case of mirtrons (57). The TAR
element in HIV-1 having structural similarities with
human pre-miRNA let-7a-3 (15) is too short for Drosha
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1038 Nucleic Acids Research, 2009, Vol. 37,No. 4processing whose pri-miRNA substrates contain a
stem of approx. three helical turns ( 33bp).
Therefore, experimental evidences suggest Drosha inde-
pendent processing of HIV-1 TAR miRNAs.
The pre-miRNA resulting from Drosha processing is
cleaved thereafter by cytoplasmic RNase III enzyme
Dicer acting in concert with its cofactor TRBP (transacti-
vating region RNA-binding protein) (58). The terminal
loop is removed, generating the miRNA duplex intermedi-
ate. Dicer facilitates assembly of the miRNA strand
(having weaker 50 bp) of the duplex into the miRNA eﬀec-
tor complexes, called RNA-induced silencing complexes
(RISCs) (58). The unincorporated strand termed as ‘pas-
senger strand’ is released and degraded. Although the
composition of RISC is not completely deﬁned, the key
constituents of it are miRNA and one of the four
Argonaute (Ago) proteins (59). The miRNA then directs
RISC to complementary mRNAs (60), which is either
cleaved or undergone translational repression depending
on the degree of complementarity between the RISC-
bound miRNA and the target mRNA. A seed sequence
within the miRNA (nts 2–8) is known to be critical for
binding and target recognition. Perfect complementarity
results in mRNA degradation/cleavage, which is rare in
animals but not in plants. Such an example is exhibited by
the polyoma virus SV40 miRNAs, which are perfectly
complementary to early mRNAs transcribed antisense to
the pre-miRNA and direct the RISC-mediated cleavage of
these early transcripts, responsible for generating strong
cytotoxic T-cell (20). In major instances, imperfect/partial
complementarity with the target is observed, leading to
translational repression of the mRNA transcripts by
miRNA-RISC (61,62). In addition to repressing transla-
tion, miRNA interactions can lead to deadenylation or
target decapping, leading to rapid mRNA decay (63–66).
miRNA editing influences processing pathway
The levels of mature miRNAs expressed within a cell are
not simply determined by the transcription of miRNA
genes; rather it depends on one or more steps in the pro-
cessing pathway (67) like RNA editing of pri-/pre-
miRNAs. Edited pri-/pre-miRNAs do not undergo
Drosha or Dicer cleavage, which eventually reduces the
production of mature miRNAs. In certain cases, pri-
miRNAs are transported out of the nucleus into the cyto-
plasm where Drosha fails to process them and they are
destroyed (68). Adensosine deaminase editing of speciﬁc
pri-miRNAs has been reported. This A-I editing event
leads to decreased processing of the miRNA by Drosha
and increases turnover by the Tudor-SN nuclease, a com-
ponent of RISC and also a ribonuclease speciﬁc to
inosine-containing dsRNAs (69). The human and mouse
pre-miRNAs of miR-22 are edited at several positions,
including sites in the mature miRNA, which are predicted
to inﬂuence its biogenesis and function (70). Notably, the
viral miRNA, kshv-miR-K12-10, with a single adenosine
residue substituted by guanosine (miR-K12-10b) is fre-
quently detected among cDNA isolates identiﬁed by the
small RNA-cloning method. The editing of this particular
site does not inhibit pri-miR-K12-10 RNA processing, but
leads to expression of mature miRNA with the edited
sequence (10). Evidence of RNA editing has also been
observed in miR-M7 of MDV, although its eﬀect is
unknown (38). However, RNA editing in the seed
sequence of a miRNA could re-direct it to a new set of
targets (71). All these indicate that the miRNAs originated
from the same pre-miRNA may target more correspond-
ing complementary mRNA, making the ﬁne-tuning of the
virus-host interaction network more complicated.
EVOLUTIONARY ASPECTS OF CELLULAR
VERSUS VIRAL miRNA GENES
Cellular miRNAs and their target sequences are fre-
quently conserved (72), which facilitate computational
biologists toward in silico prediction of cellular miRNAs
and their targets. Interestingly, viral miRNAs, unlike their
vertebrate counterparts do not share a high level of
homology, even within members of the same family or
with that of the host. However, miRNAs of closely related
viruses such as RRV and KSHV are encoded in the same
genomic region but do not exhibit sequence homology
(31). The miRNAs encoded by chicken a-herpesviruses
MDV-1 and MDV-2 are clustered in homologous regions
of the viral genomes, which are transcribed during viral
latency, but are not homologous in sequence (36–38). In
contrary to these, Cai et al. (28) have shown that eight of
EBV miRNAs are conserved with rLCV miRNAs, thus
arguing for their importance in viral life cycle.
The lack of conservation in viral miRNA sequences
attributes to the higher rate of mutations and faster
Figure 1. Biogenesis of microRNAs. Processing of both host miRNAs
(violet) and virus-encoded miRNAs (blue) is assumed to occur through
the same pathway. The arrows (pink) indicate the eﬀects of cellular
miRNAs on their own cellular transcripts as well as on viral transcripts.
The violet arrow shows the eﬀects of virus-encoded miRNAs on both
cellular and viral transcripts. Both these arrows suggest possible
miRNA-mediated interactions between viruses and their hosts.
Nucleic Acids Research,2009, Vol.37, No. 4 1039evolution in viruses when compared to eukaryotes.
This would mean an evolutionary advantage for rapid
adaptation to the host and environmental conditions.
However, it oﬀers a challenge to computational biologists
as most of the algorithms for miRNA prediction rely
heavily on conservation and would prove inadequate in
case of viruses. Even a single-point mutation in the seed
region can lead to a dramatic shift in miRNA function due
to the loss or acquisition of a large number of cellular or
viral mRNA targets.
VIRUS-ENCODED miRNAs—ORTHOLOGS OF
CELLULAR miRNAs
In general, viral miRNAs and cellular miRNAs do not
bear seed homology. But presumably, due to the presence
of highly evolved gene-regulatory networks, some viral
miRNAs have seed homology with cellular miRNAs.
Recent report suggests that miR-K12-11 encoded by
KSHV shares the ﬁrst eight nts with hsa-miR-155
(27,73) (refer Figure 2). MiR-155 is processed from a pri-
mary transcript, termed as BIC gene (B-cell Integration
Cluster), whose upstream region was identiﬁed as a
common site of integration of the avian leucosis virus
(ALV) (74) in lymphomas. miRNA-proﬁling studies
have shown increased expression of miR-155 in a wide
range of cancers including lymphomas (75). Gottwein
et al. (73) reported that miR-155 and miR-K12-11 regulate
similar set of targets including genes with known roles in
cell-growth regulation. It has been shown that BACH-1 is
one of the predicted mRNAs, targeted by both miR-155
and miR-K12-11 (27). Transient expression of miR-155
occurs in macrophages, T and B lymphocytes and miR-
155 knockout mice revealed defects in adaptive immune
responses. Furthermore, overexpression of miR-155 in
B-cells is associated with the development of B-cell lym-
phomas in humans, mice and chickens (74) although the
mechanism is unknown. Given the apparent role of miR-
155 in tumorigenesis and miR-K12-11 being an ortholog
of miR-155, it is tempting to speculate that miR-K12-11
may contribute to the development of B-cell tumors seen
in KSHV-infected individuals. Inspite of being a distantly
related g-herpesvirus, EBV miRNAs do not bear homol-
ogy to miR-155 (76). However, previous reports have
shown the expression of BIC during EBV infection expres-
sing the full repertoire of EBV latency genes, which
implies the role of EBV latency genes in inducing BIC
gene (77).
Analyzing the entire set of viral miRNAs known till
today, such seed homology is observed in a few more
cases. One of the interesting cases is the MDV-1 miRNA
miR-M4, which bears the same 5
/terminal 8nts as miR-
K12-11 and hence might function as an ortholog of miR-
155. Since MDV-1 encodes meq oncogene apart from
other proteins, miR-M4 might contribute to tumorigenesis
in chickens. Furthermore, miR-M1-4 of MHV68 shares
5
/terminal 9nts with murine miR-151. The function of
this cellular miRNA is still unknown. Potential cellular
orthologs of other viral miRNAs having limited seed
homology (nts 2–7) (refer Figure 2), corresponding to
the minimal miRNA seed region, include ebv-miR-
BART5, rlcv-miR-rL1-8 and mghv-miR-M1-7-5p, which
have miR-18a and miR-18b as their cellular counterpart.
These two cellular miRNAs are encoded in the miR-17-92
cluster, which has oncogenic function (78).
VIRAL miRNAs-REGULATING GENE EXPRESSION
Regulatory impact on viral transcripts
Viral miRNAs have a regulatory eﬀect on their protein-
coding genes. The level of regulation depends on the
degree of complementarity of the viral miRNAs with the
3
/UTR (untranslated region) of the regulated mRNAs
(79). These regulations are beneﬁciary to the virus
toward maintaining its replication, latency and evading
the host-immune system (Figure 3).
MiR-BART2 of EBV exhibits perfect complementarity
to the 3
/UTR of BALF5, which encodes the viral DNA
polymerase (9). Recently, Barth et al. (14) have shown that
miR-BART2 down-regulates BALF5. Induction of the
lytic viral replication cycle results in a reduction of
the level of miR-BART2. Hence, there is a decrease in
cleavage of the BALF5 3
/UTR. Forced expression
of miR-BART2 during lytic replication resulted in a
40–50% reduction of the level of BALF5 protein and
Figure 2. Virus-encoded microRNAs as orthologs of cellular
microRNAs. Encircled boxes show sequence homology of viral
miRNAs to human/mouse miRNAs. The homologous bases are
shown in blue. (a) Orthologs of cellular miR-155; (b) orthologs of cel-
lular miR-151; (c) orthologs of cellular miR-18a and miR-18b.
1040 Nucleic Acids Research, 2009, Vol. 37,No. 4a 20% reduction of the amount of virus released from
EBV-infected cells. It might be the situation that latently
expressed miR-BART2 speciﬁcally has evolved to target
BALF5, and such an interaction may be essential for
maintaining EBV latency. The other EBV miRNAs
miR-BART-1p, miR-BART16 and miR-BART17-5p
(having imperfect match with the targets) target 3
/UTR
of the mRNA coding for the latency-associated membrane
protein LMP-1 and repress its expression. This regulation
decreases LMP-1-mediated activation of nuclear factor-
kappa B (NF-kB) as well as apoptosis resistance (44).
Hence, these miR-BART miRNA-mediated regulations
on LMP1 may explain the discrepancy between LMP1
transcript and protein detection in nasopharyngeal carci-
noma. This further highlights the role of the EBV
miRNAs in regulating LMP1 downstream signaling to
promote cancer development (44).
Grey et al. (79) predicted that miR-UL112-1 of
HCMV targets the viral immediate-early protein 1(IE1)
mRNA, a transcription factor required for the expression
of many viral genes. To test this prediction, mutant viruses
were generated that were unable to express miRNA or
encoded an IE1 mRNA lacking its target site. Analysis
of RNA and protein within infected cells demonstrated
that miR-UL112-1 inhibits expression of the major IE1
protein. Such miRNA-mediated suppression of IE genes
might be a part of the strategy of these viruses to enter the
host and maintain latency.
SV40 miRNAs (miR-S1-5p and miR-S1-3p) are per-
fectly complementary to early viral mRNAs and target
the mRNAs for a protein known as T antigen, leading
to its cleavage. On entering into the cell, viral replication
is triggered by the production of this T antigen.
Furthermore, T antigen serves as a target for host
immune (T) cells, which destroys infected cells and pre-
vents the virus from spreading. Thus, the corresponding
miRNAs (targeting T antigenic mRNA) accumulate at
late times in infection when enough viral replication has
been done. Furthermore, it has been shown that cells
infected with a mutant virus (that does not produce
SVmiRNAs) are more likely to get killed by cytotoxic
immune cells rather than the wild-type ones (11). Thus,
it is shown that viral evolution has taken advantage of the
miRNA pathway to generate eﬀectors that enhance the
probability of successful infection.
MDV latency-associated transcripts include miR-M6 to
miR-M8 and miR-M10 and miR-M13, which maps to a
large intron at the 50 end (38,80). This is presumably
derived from a large 10-kb transcript that maps antisense
to the ICP4 gene, which implies a probable role of these
miRNAs toward modulating ICP4 transcript to inhibit
entry of the virus into the lytic cycle.
In HIV-1-infected and nef-transduced cells, nef-
derived miRNA miR-N367 inhibits HIV-1 transcription
inhumanTcells(46),thusfacilitatingbothviralreplication
and disease progression. Recently, annotated HSV-1
miRNAs, miR-H2-3p and miR-H6 are reported to down-
regulate the expression of ICP0 and ICP4 proteins, respec-
tively. Such miRNA-induced down-regulation helps HSV-
1 to maintain latency (16). Furthermore, miR-I of HSV-2
regulates expression of a key viral neurovirulence
factor, thereby aﬀecting the establishment of latency (34).